Prednisonum
Rectodelt contains the active substance prednisone, which is a glucocorticosteroid (corticosteroid) that affects metabolism, electrolyte balance, and tissue function.
Rectodelt is used in infants, young children, and children to treat acute episodes of croup (acute laryngitis and tracheitis with airway obstruction), croup, and exacerbations of asthma or acute wheezing episodes.
if the patient is allergic to prednisone or any of the other ingredients of this medicine (listed in section 6).
There are no other known contraindications to short-term use of Rectodelt in the treatment of acute conditions.
Taking this medicine may cause a crisis in the course of a pheochromocytoma (adrenal gland tumor), which can lead to death. Pheochromocytoma is a rare adrenal gland tumor. A crisis in its course may manifest as headache, excessive sweating, palpitations, and increased blood pressure. If these symptoms occur, the patient should contact their doctor immediately.
Before starting treatment with Rectodelt, the patient should discuss it with their doctor or pharmacist,
if the patient or their parent experiences blurred vision or other vision disturbances.
if the patient or their parent has been diagnosed with pheochromocytoma (adrenal gland tumor) or is suspected of having it.
Taking Rectodelt may result in positive doping test results.
Taking Rectodelt as a doping agent can pose a risk to health.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those available without a prescription.
What other medicines affect the action of Rectodelt?
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
There is insufficient data on the use of Rectodelt in pregnant women. In animal studies, glucocorticosteroids have shown harmful effects on the unborn animal.
This effect is also possible in humans. If the patient is pregnant, they should only use Rectodelt if their doctor considers it necessary.
The active substance in Rectodelt passes into breast milk. With high doses or prolonged use, breastfeeding should be discontinued.
Rectodelt has no influence or negligible influence on the ability to drive and use machines.
This medicine should always be used as directed by a doctor or pharmacist. If in doubt, consult a doctor or pharmacist.
Recommended dose.
Infants, young children, and children are given one suppository, which corresponds to 100 mg of prednisone. If necessary, the administration should be repeated no more than once. A second suppository may be given within 12-24 hours. Further use is not recommended. The total dose should not exceed 2 suppositories (equivalent to 200 mg of prednisone). The duration of treatment should not exceed two days.
Method of administration:
The medicine is used rectally.
The suppository should be inserted deeply into the rectum.
Note: Do not exceed the recommended dose and duration of use, as this may result in serious side effects (Cushing's syndrome, see section 4).
Rectodelt is generally well-tolerated without complications, even if large amounts are used for a short time.
No special measures are required. If the patient experiences severe or unusual side effects, they should consult their doctor.
If you have any further doubts about using this medicine, consult a doctor or pharmacist.
Like all medicines, Rectodelt can cause side effects, although not everybody gets them.
Apart from the possibility of an allergic reaction to Rectodelt (see section 2), no side effects are expected in the treatment of acute conditions. Long-term administration may lead to side effects typical of corticosteroids (Cushing's syndrome symptoms), such as: moon face, central obesity, edema (tissue swelling), increased potassium excretion, decreased glucose tolerance, growth retardation in children, hormonal disturbances, skin changes, muscle weakness, osteoporosis, mental changes, increased blood pressure, and changes in blood morphology. These symptoms may occur to varying degrees. The following may also occur: gastrointestinal disorders, pancreatitis, increased vascular fragility, increased risk of infection, increased intraocular pressure (glaucoma), and blurred vision.
Frequency not known: bradycardia (slow heart rate).
Scleroderma renal crisis in patients with systemic scleroderma. Symptoms of scleroderma renal crisis include high blood pressure and decreased urine production.
Systemic effects of glucocorticosteroids may occur after administration of Rectodelt, probably depending on the dose, exposure time, concurrent and previous exposure to corticosteroids, and individual sensitivity. These may include: adrenal insufficiency, growth retardation in children and adolescents, decreased bone mineral density, cataracts, and increased intraocular pressure (glaucoma), as well as an increased susceptibility to infections. The ability to adapt to stress may be impaired.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects can help gather more information on the safety of the medicine.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Rectodelt is a white or almost white torpedo-shaped suppository.
Rectodelt is available in PVC/PE blisters in a cardboard box, in packs containing 2, 4, or 6 suppositories.
For more detailed information, consult the marketing authorization holder or parallel importer.
Trommsdorff GmbH & Co. KG
Trommsdorffstrasse 2-6
524 77 Alsdorf
Germany
Trommsdorff GmbH & Co. KG
Trommsdorffstrasse 2-6
524 77 Alsdorf
Germany
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in the Czech Republic, the country of export:56/086/98-C
Parallel import authorization number:167/25
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.